The health department is considering shortening breast cancer treatment for patients eligible for Roche’s costly trastuzumab, in the wake of a large study that found halving the duration of therapy to six months was just as effective as a year, and reduced the risk of dangerous heart problems.

The high cost of trastuzumab has been a barrier to treatment in both the public and private sector in SA. The health department only added it to its treatment guidelines in 2017, and provision of the drug by provincial health departments has remained limited due to its price.

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Times Select.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now